Drug intelligence / Profile preview

PF-06952229 + enzalutamide

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

PF-06952229 + enzalutamide is an investigational combination therapy consisting of PF-06952229, a selective, small molecule inhibitor of transforming growth factor-β receptor 1 (TGF-β-R1), and enzalutamide, an androgen receptor inhibitor approved for the treatment of prostate cancer. This combination is being studied primarily for metastatic castration-resistant prostate cancer (mCRPC), with the goal of improving anti-tumor efficacy by targeting both the TGF-β pathway (which is implicated in cancer progression and epithelial-mesenchymal transition) and androgen receptor signaling. PF-06952229 is being developed by Pfizer[1][3][5].

Targets

AR (Adrenergic receptors)TGFBR1

Beyond the preview

Go deeper on PF-06952229 + enzalutamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-06952229 + enzalutamide.

Explore the full profile